

Mendus Q3 2024 - Minor catalysts in Q4 2024e, CADENCE in focus

Redeye provides its comment on Mendus' Q3 2024 report. We judge ADVANCE II and ALISON readouts might act as minor catalysts in Q4 2024e. We believe CADENCE readouts will be major catalysts in the coming 12-24 months. Its estimated funding runway extends past several of these catalysts. We update our deal estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Mendus Q3 2024 - Minor catalysts in Q4 2024e, CADENCE in focus](#)